

Optimizing In Vitro Candidates for Radiopharmaceutical Development

Overcoming preclinical challenges around radionuclide selection, biodistribution, circulation, and clearance.

Key webinar takeaways

- **A promising in vitro candidate does not guarantee a successful radiopharmaceutical.**
Bioconjugation and/or radiolabeling can alter biological performance. Binding and biodistribution should be reassessed before progressing to efficacy studies.
- **Radionuclide selection should reflect the intended application and pharmacokinetics.**
Emission type and physical half-life must suit the diagnostic or therapeutic objective and the time required for targeting and clearance.
- **Radionuclide availability is a development consideration from the outset.**
Production capacity, shipment times and scalability should be considered early to support studies and subsequent clinical development.
- **Chelator and conjugation chemistry can substantially affect biodistribution.**
The same targeting vector and radionuclide can produce markedly different tumor and organ uptake depending on the chelator and how it is attached.
- **Structural modifications can improve targeting and clearance, but involve trade-offs.**
Molecular size, charge, albumin binders and cleavable linkers can improve tumor uptake and renal retention. Longer circulation also requires careful assessment of background exposure.
- **Reducing renal uptake may be possible without redesigning the targeting molecule.**
Co-administration of protective agents reduced kidney uptake in the examples presented, demonstrating the value of evaluating treatment regimens alongside molecular modifications.
- **Pretargeting separates tumor targeting from radionuclide delivery.**
A targeting vector is administered before a rapidly clearing radiolabeled effector. This can enable shorter-lived radionuclides and reduce radiation exposure in non-target tissues.
- **Successful pretargeting requires optimization of both components and timing.**
The vector must remain accessible at the tumor, while the effector must bind efficiently and clear rapidly. The dosing interval must balance vector clearance with target accessibility.

If you would like to learn more about optimizing candidates for radiopharmaceutical development, please contact our team:

contact@oncodesign-services.com | oncodesign-services.com

